Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

SYGNIS Licenses Amplification Buffer to QIAGEN

Published: Thursday, May 16, 2013
Last Updated: Thursday, May 16, 2013
Bookmark and Share
This is the second agreement with QIAGEN within 9 months.

Spanish-German biotech company SYGNIS Pharma AG has signed a licence agreement for the distribution of a new amplification buffer with QIAGEN. This is the first licence agreement for the amplification buffer technology developed by the team led by renowned Professor Margarita Salas at the CSIC laboratory.

The recently granted licence covers a new amplification buffer, a tool used in isothermal amplification, providing superior reaction performance.

“With the new agreement, SYGNIS adds a global reference in the sector in the fields of DNA amplification research and commercial markets. This newly signed agreement shows that SYGNIS is making progress in the commercialization of core technologies and products designed for the DNA sequencing and amplification market. It strengthens the network of relationships we maintain with life science and diagnostics companies in the DNA amplification industry,” SYGNIS’ CEO Pilar de la Huerta commented.


In July 2012, through X-POL, SYGNIS reached an exclusive global licence agreement with QIAGEN for the distribution of the polymerase QualiPhi®.

QualiIPhi® is an upgraded version of phi 29 DNA polymerase. Compared to similar polymerase proteins on the market, the new one exhibits enhanced properties. Being less time-consuming and having highly superior performance characteristics, the method developed by SYGNIS enables DNA amplification from concentrations as low as those found in a single cell. This is extremely useful in cancer research, among other applications.

Polymerase proteins are the main tool for amplifying long DNA fragments and whole genomes, and are basic in research involving analysis and modification of DNA from any species.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SYGNIS Reports Financial Results for Fiscal Year 2014
Successful change in product and commercialization strategy with strong focus on proprietary product portfolio.
Saturday, May 09, 2015
SYGNIS Signs Non-exclusive Distribution Agreement with Cambridge Bioscience
Significant expansion of product roll-out into one of the most important life science markets in Europe.
Tuesday, May 05, 2015
SYGNIS Signs Non-Exclusive Distribution Agreement with SOPACHEM
SOPACHEM is a specialized distributor with focus on life sciences, diagnostics, biobanking and analytical applications.
Thursday, March 19, 2015
SYGNIS Reports Financial Results for Fiscal Year 2012
Strategic realignment completed - discontinuation of drug development.
Wednesday, May 01, 2013
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos